Interview with Professor Stephen Powis

The video discusses the significant milestone in the UK's vaccination program with the introduction of the Moderna vaccine. It highlights the progress made with over 27 million first doses and 6 million second doses administered. The Moderna vaccine will complement existing vaccines and is particularly suitable for adults aged 18-29. Initially deployed in larger centers, its use will expand as supply increases. The Moderna vaccine offers logistical advantages over Pfizer, being easier to store and distribute. The UK has ordered 17 million doses, ensuring the program remains on track to vaccinate all adults by summer.

What milestone was achieved in the vaccination program with the introduction of the Moderna vaccine?

• Completion of the first phase of vaccinations

• Introduction of a third type of vaccine

• End of the vaccination program

• Vaccination of all healthcare workers

For which age group is the Moderna vaccine particularly recommended as an alternative?

• 30 to 40 years

• Under 18 years

• 18 to 29 years

• 50 to 60 years

What is one logistical advantage of the Moderna vaccine over the Pfizer vaccine?

• It requires no refrigeration

• It can be stored in a normal freezer

• It is cheaper to produce

• It has a longer shelf life

How many doses of the Moderna vaccine has the UK ordered?

• 17 million

• 25 million

• 5 million

• 10 million

By when does the program aim to offer the vaccine to all adults?

• By the summer

• By the end of the year

• By the autumn

• By next spring